Table 2.
Univariate analysis of factors regarding overall survival (OS) and recurrence-free survival (RFS)
| Variable | Categorisation | Tumour-related death (OS) | Tumour recurrence (RFS) | ||||
| n | events | pc | n | events | pc | ||
| Clinicopathological data: | |||||||
| Tumour stagea | |||||||
| pT1 | 61 | 11 | 0.001 | 59 | 14 | <0.0001 | |
| pT2 | 96 | 34 | 93 | 43 | |||
| pT3 | 14 | 5 | 13 | 7 | |||
| pT4 | 28 | 17 | 26 | 18 | |||
| Lymph node statusa | |||||||
| pN0 | 89 | 15 | <0.0001 | 87 | 17 | <0.0001 | |
| pN1-3 | 105 | 46 | 102 | 60 | |||
| Histological grade | |||||||
| G1 | 22 | 5 | 0.003 | 21 | 6 | 0.001 | |
| G2 | 90 | 23 | 86 | 29 | |||
| G3 | 87 | 39 | 85 | 46 | |||
| Multifocality | |||||||
| unifocal tumour | 174 | 55 | 0.165 | 168 | 70 | 0.348 | |
| multifocal tumour | 27 | 12 | 25 | 12 | |||
| Histological type | |||||||
| ductal | 165 | 53 | 0.333 | 162 | 70 | 0.494 | |
| lobular | 15 | 8 | 13 | 6 | |||
| other | 18 | 6 | 16 | 5 | |||
| Immunohistochemistry (IHC): | |||||||
| Oestrogen receptor status | |||||||
| negative | 57 | 24 | 0.027 | 57 | 29 | 0.057 | |
| positive | 103 | 27 | 99 | 33 | |||
| Progesterone receptor status | |||||||
| negative | 115 | 49 | 0.001 | 109 | 52 | 0.015 | |
| positive | 53 | 8 | 53 | 14 | |||
| HER2 IHC | |||||||
| weak (0–2+) | 142 | 42 | 0.055 | 135 | 53 | 0.120 | |
| strong (3+) | 31 | 14 | 31 | 16 | |||
| FOXM1b | |||||||
| negative (IRS 0–1) | 56 | 14 | 0.110 | 54 | 23 | 0.581 | |
| positive (IRS 2–12) | 146 | 53 | 140 | 59 | |||
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bFOXM1 nuclear immunoreactivity: negative = IRS 0–1, positive = IRS 2–12
cLog-rank test (two-sided), bold face representing significant data (P < 0.05)